Dupixent® (dupilumab) FDA Approved as First and Only ...
Jan 25, 2024 · TARRYTOWN, N.Y. and PARIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug …
DUPIXENT® (dupilumab) For Eosinophilic Esophagitis
Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb …
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 ...
Jun 27, 2024 · Dupilumab resulted in histologic remission in a significantly higher percentage of children with eosinophilic esophagitis than placebo. The higher-exposure dupilumab regimen also led to …
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
Dec 21, 2022 · Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. We conducted a three-part, phase 3 trial …
Jan 25, 2024 · 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients. This …
EMA approves Dupixent for young EoE patients
Nov 7, 2024 · The EMA has granted approval for Sanofi/Regeneron’s Dupixent (dupilumab) to treat EoE in children as young as one.
How effective is Dupixent for Eosinophilic Esophagitis (EOE)?
Sep 11, 2025 · Dupixent for EOE Side Effects While Dupixent for eosinophilic esophagitis is generally well tolerated, side effects most often include injection-site reactions, upper respiratory infections, …
The Disease Eosinophilic esophagitis (EoE) is a long-term, inflammatory disease of the esophagus, affecting children and adults In children, it causes symptoms such as vomiting, pain, and difficulty …
Sanofi, Regeneron Win Dupixent Label Expansion to Treat ...
Jan 26, 2024 · Sanofi and Regeneron backed Dupixent’s pediatric expansion with data from parts A and B of the Phase III EoE KIDS trial. Part A employed a tiered, weight-based dosing approach to …
FDA approves Sanofi and Regeneron's Dupixent for kids with EoE
Jan 26, 2024 · The FDA has signed off on Sanofi and Regeneron's Dupixent to treat children between the ages of 1 and 11 with eosinophilic esophagitis (EoE).